Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,072.00GBp
18 Dec 2017
Change (% chg)

-2.00 (-0.19%)
Prev Close
1,074.00
Open
1,080.00
Day's High
1,103.00
Day's Low
1,067.00
Volume
843,780
Avg. Vol
1,185,767
52-wk High
2,346.00
52-wk Low
906.50

Select another date:

Thu, Nov 30 2017

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm Biolinq​

* HIKMA PHARMACEUTICALS PLC - ‍INVESTED IN BIOLINQ IN COLLABORATION WITH M VENTURES WHICH LED $10 MILLION SERIES A ROUND OF FINANCING​ Source text for Eikon: Further company coverage:

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

BRIEF-Hikma launches serious infections treatment in the United States

* ‍CAPSULES ARE INDICATED FOR TREATMENT OF SERIOUS INFECTIONS CAUSED BY SUSCEPTIBLE STRAINS OF CANDIDA AND/OR CRYPTOCOCCUS​ Source text for Eikon: Further company coverage:

BRIEF-Hikma says US unit launched pantoprazole sodium for injection

* U.S. unit west-ward pharmaceuticals has launched pantoprazole sodium for injection, 40mg​ Source text for Eikon: Further company coverage:

Drugmaker Hikma's U.S. unit raises medicine prices: Financial Times

NEW YORK Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

NEW YORK, Aug 20 Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

UPDATE 2-Drugmaker Hikma trims sales forecasts, shares fall

Aug 17 Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

Select another date: